Targeting Hepatic Glucokinase in Type 2 Diabetes

Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ

“…Moreover, we did not find elevated triglyceride levels, as suggested by Agius [35]. GK activators have seldom been reported to decrease blood triglyceride level, indicating that the PPARγ transcription activity of this compound may mediate the lipid-lowering effect.…”

Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway

“…Impaired glucokinase activity was found in diabetic individuals [29,30]. Inactivation or the activation mutation of glucokinase gene have been linked to the development of maturity-onset diabetes of the young (MODY), Type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI) [31][32][33].…”

Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice

“…Previous studies have demonstrated that increasing mRNA levels of GK, GLUT-1 and GLUT-4, while decreasing mRNA levels of G6P, can ameliorate diabetes and that regular administration of FGF-21 might increase the expression of GLUT-1 and GK while decreasing G6P gene expression in the liver [42][43][44][45][46]. The present study's real-time PCR results show that PEGylated FGF-21 can significantly increase gene expression of GLUT-1 and GK and decrease G6P expression in the liver compared with insulin glargine, which brought about glucose homoeostasis through upregulation of GLUT-4 in WAT.…”